Cargando…
Oxalate Oxidase for In Situ H(2)O(2)‐Generation in Unspecific Peroxygenase‐Catalysed Drug Oxyfunctionalisations
H(2)O(2)‐driven enzymes are of great interest for industrial biotransformations. Herein, we show for the first time that oxalate oxidase (OXO) is an efficient in situ source of H(2)O(2) for one of these biocatalysts, which is known as unspecific peroxygenase (UPO). OXO is reasonably robust, produces...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805127/ https://www.ncbi.nlm.nih.gov/pubmed/35916874 http://dx.doi.org/10.1002/anie.202207831 |
_version_ | 1784862272486637568 |
---|---|
author | Romero, Elvira Johansson, Magnus J. Cartwright, Jared Grogan, Gideon Hayes, Martin A. |
author_facet | Romero, Elvira Johansson, Magnus J. Cartwright, Jared Grogan, Gideon Hayes, Martin A. |
author_sort | Romero, Elvira |
collection | PubMed |
description | H(2)O(2)‐driven enzymes are of great interest for industrial biotransformations. Herein, we show for the first time that oxalate oxidase (OXO) is an efficient in situ source of H(2)O(2) for one of these biocatalysts, which is known as unspecific peroxygenase (UPO). OXO is reasonably robust, produces only CO(2) as a by‐product and uses oxalate as a cheap sacrificial electron donor. UPO has significant potential as an industrial catalyst for selective C−H oxyfunctionalisations, as we confirm herein by testing a diverse drug panel using miniaturised high‐throughput assays and mass spectrometry. 33 out of 64 drugs were converted in 5 μL‐scale reactions by the UPO with OXO (conversion >70 % for 11 drugs). Furthermore, oxidation of the drug tolmetin was achieved on a 50 mg scale (TON(UPO) 25 664) with 84 % yield, which was further improved via enzyme immobilization. This one‐pot approach ensures adequate H(2)O(2) levels, enabling rapid access to industrially relevant molecules that are difficult to obtain by other routes. |
format | Online Article Text |
id | pubmed-9805127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98051272023-01-06 Oxalate Oxidase for In Situ H(2)O(2)‐Generation in Unspecific Peroxygenase‐Catalysed Drug Oxyfunctionalisations Romero, Elvira Johansson, Magnus J. Cartwright, Jared Grogan, Gideon Hayes, Martin A. Angew Chem Int Ed Engl Communications H(2)O(2)‐driven enzymes are of great interest for industrial biotransformations. Herein, we show for the first time that oxalate oxidase (OXO) is an efficient in situ source of H(2)O(2) for one of these biocatalysts, which is known as unspecific peroxygenase (UPO). OXO is reasonably robust, produces only CO(2) as a by‐product and uses oxalate as a cheap sacrificial electron donor. UPO has significant potential as an industrial catalyst for selective C−H oxyfunctionalisations, as we confirm herein by testing a diverse drug panel using miniaturised high‐throughput assays and mass spectrometry. 33 out of 64 drugs were converted in 5 μL‐scale reactions by the UPO with OXO (conversion >70 % for 11 drugs). Furthermore, oxidation of the drug tolmetin was achieved on a 50 mg scale (TON(UPO) 25 664) with 84 % yield, which was further improved via enzyme immobilization. This one‐pot approach ensures adequate H(2)O(2) levels, enabling rapid access to industrially relevant molecules that are difficult to obtain by other routes. John Wiley and Sons Inc. 2022-08-25 2022-09-26 /pmc/articles/PMC9805127/ /pubmed/35916874 http://dx.doi.org/10.1002/anie.202207831 Text en © 2022 The Authors. Published by Wiley-VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Communications Romero, Elvira Johansson, Magnus J. Cartwright, Jared Grogan, Gideon Hayes, Martin A. Oxalate Oxidase for In Situ H(2)O(2)‐Generation in Unspecific Peroxygenase‐Catalysed Drug Oxyfunctionalisations |
title | Oxalate Oxidase for In Situ H(2)O(2)‐Generation in Unspecific Peroxygenase‐Catalysed Drug Oxyfunctionalisations
|
title_full | Oxalate Oxidase for In Situ H(2)O(2)‐Generation in Unspecific Peroxygenase‐Catalysed Drug Oxyfunctionalisations
|
title_fullStr | Oxalate Oxidase for In Situ H(2)O(2)‐Generation in Unspecific Peroxygenase‐Catalysed Drug Oxyfunctionalisations
|
title_full_unstemmed | Oxalate Oxidase for In Situ H(2)O(2)‐Generation in Unspecific Peroxygenase‐Catalysed Drug Oxyfunctionalisations
|
title_short | Oxalate Oxidase for In Situ H(2)O(2)‐Generation in Unspecific Peroxygenase‐Catalysed Drug Oxyfunctionalisations
|
title_sort | oxalate oxidase for in situ h(2)o(2)‐generation in unspecific peroxygenase‐catalysed drug oxyfunctionalisations |
topic | Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805127/ https://www.ncbi.nlm.nih.gov/pubmed/35916874 http://dx.doi.org/10.1002/anie.202207831 |
work_keys_str_mv | AT romeroelvira oxalateoxidaseforinsituh2o2generationinunspecificperoxygenasecatalyseddrugoxyfunctionalisations AT johanssonmagnusj oxalateoxidaseforinsituh2o2generationinunspecificperoxygenasecatalyseddrugoxyfunctionalisations AT cartwrightjared oxalateoxidaseforinsituh2o2generationinunspecificperoxygenasecatalyseddrugoxyfunctionalisations AT grogangideon oxalateoxidaseforinsituh2o2generationinunspecificperoxygenasecatalyseddrugoxyfunctionalisations AT hayesmartina oxalateoxidaseforinsituh2o2generationinunspecificperoxygenasecatalyseddrugoxyfunctionalisations |